In this latest instalment of our video series exploring the scientific and investment implications of COVID-19, Portfolio Manager Andy Acker and Biotech Analyst Agustin Mohedas discuss lessons learned as economies reopen, the virus’ fatality rate and the latest news in vaccine development.

  Key takeaways

  • Practices such as social distancing and contact tracing appear vital to containing the spread of the COVID-19 coronavirus. In countries that have aggressively used these measures, the number of daily new cases has dropped dramatically. In areas that have not, case levels are, at best, holding steady.
  • New data indicate that the infection fatality rate for COVID-19 is between 1% to 1.5%, making the coronavirus roughly ten times more deadly than the flu.
  • Early clinical data for several vaccine candidates look promising, with results showing that the vaccines can generate neutralising antibodies that kill the virus.